387 related articles for article (PubMed ID: 10343018)
1. Stoning a dead bird: advertising limits on approved new drugs.
Strobos J
Food Drug Law J; 1995; 50(4):533-51. PubMed ID: 10343018
[No Abstract] [Full Text] [Related]
2. What drug labels don't tell you.
Consum Rep; 2011 Aug; 76(8):10. PubMed ID: 21770080
[No Abstract] [Full Text] [Related]
3. Regulation of pharmacoeconomics and outcomes research.
Radensky P
Value Health; 2001; 4(1):12-5. PubMed ID: 11704968
[No Abstract] [Full Text] [Related]
4. Regulating manufacturer-affiliated communication in the information age.
Schulman KA; Abernethy DR; Rathore SS; Woosley RL
Clin Pharmacol Ther; 1999 Jun; 65(6):593-7. PubMed ID: 10391664
[No Abstract] [Full Text] [Related]
5. Is it worth the trouble? The new policy on dissemination of information on off-label drug use under the Food and Drug Administration Modernization Act of 1997.
Weeks EA
Food Drug Law J; 1999; 54(4):645-65. PubMed ID: 11824459
[No Abstract] [Full Text] [Related]
6. Direct-to-consumer prescription drug advertising.
Terzian TV
Am J Law Med; 1999; 25(1):149-67. PubMed ID: 10207573
[No Abstract] [Full Text] [Related]
7. Benefit and risk information in prescription drug advertising: review of empirical studies and marketing implications.
Kopp SW; Bang HK
Health Mark Q; 2000; 17(3):39-56. PubMed ID: 11010219
[TBL] [Abstract][Full Text] [Related]
8. The First Amendment and FDA restrictions on off-label uses: the call for a new approach.
Leghorn J; Brophy E; Rother P
Food Drug Law J; 2008; 63(2):391-406. PubMed ID: 18561466
[No Abstract] [Full Text] [Related]
9. Rules set for dissemination of off-label-use information.
Miller JL
Am J Health Syst Pharm; 1999 Feb; 56(3):204. PubMed ID: 10030500
[No Abstract] [Full Text] [Related]
10. FDA Modernization Act: implications for oncology.
Morris L
Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
[TBL] [Abstract][Full Text] [Related]
11. Major issues in marketing regulation.
Pines WL
Food Drug Law J; 1997; 52(3):297-302. PubMed ID: 10343028
[No Abstract] [Full Text] [Related]
12. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
13. A defense of the learned intermediary doctrine.
Goetz RB; Growdon KR
Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470
[No Abstract] [Full Text] [Related]
14. Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.
Strawn MN
J Contemp Health Law Policy; 2003; 19(2):495-520. PubMed ID: 14748255
[No Abstract] [Full Text] [Related]
15. Direct-to-OTC marketing of drugs: possible approaches.
Mahinka SP; Bierman ME
Food Drug Law J; 1995; 50(1):49-63. PubMed ID: 10342985
[No Abstract] [Full Text] [Related]
16. Communicating with patients about their medications.
Kessler DA
N Engl J Med; 1991 Dec; 325(23):1650-2. PubMed ID: 1944456
[No Abstract] [Full Text] [Related]
17. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
18. How should FDA regulate prescription drug promotion on the Internet?
Opderbeck DW
Food Drug Law J; 1998; 53(1):47-61. PubMed ID: 11795336
[TBL] [Abstract][Full Text] [Related]
19. Off-label drug use.
Dooley AG
Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258
[No Abstract] [Full Text] [Related]
20. FDA's Rx for better medication information.
Farley D
FDA Consum; 1995 Nov; 29(9):5-10. PubMed ID: 10152787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
